Endo International PLC said it executed a settlement agreement to resolve all product liability claims against the company's testosterone therapy.
Endo was facing hundreds of lawsuits accusing the company of hiding the health risks of using its testosterone-boosting drug, Testim. The lawsuits alleged that the drug, which Endo co-markets with GlaxoSmithKline PLC to middle-aged men, caused potentially fatal blood clots that caused heart attacks and strokes.
Dublin-based Endo will make an undisclosed payment to settle the claims. The settlement does not involve an admission of wrongdoing or liability.
Further, Endo also announced a significant case management order by Judge Matthew Kennelly, who was overseeing the lawsuits against the company, requiring claimants who chose not to participate in the settlement to produce certain information within a time frame.
Endo is not the only drugmaker facing lawsuits for their testosterone-boosting therapies. In January, Eli Lilly and Co. agreed to settle more than 400 cases filed against it regarding its own testosterone replacement treatment, Axiron.
In the same month, AbbVie Inc. won a trial related to the marketing of AndroGel, a Testim rival. A federal jury in Chicago found that the company was not liable in a lawsuit accusing AndroGel of causing pulmonary embolism, or an artery blockage in the lung usually caused by a blood clot.
